OXFORD, UK – 8 June, 2022 – Sitryx Therapeutics Ltd (the “Company”), a biopharmaceutical company pioneering the field of immunometabolism, today announced that Neil Weir, Chief Executive Officer of Sitryx, will present at the 2022 BIO International Convention being held June 13-16, 2022 in San Diego, CA. The presentation will take place on Monday, June 13th, 2022 at 4:15 PM PT in Theater 4 of the San Diego Convention Center, located at 111 W Harbor Drive, San Diego, CA 92101.
To schedule a meeting with Company management during BIO, please submit a request through the One-on-One Partnering™ system.
About Sitryx Therapeutics
Sitryx is a global biopharmaceutical company pioneering the field of immunometabolism. The company’s proprietary platform and Product Engine are built on a deep understanding of the intersection of inflammatory signaling and metabolism. Sitryx is advancing a pipeline of disease-modifying therapies towards the clinic, on its own and with its strategic partner, Eli Lilly and Company, for a wide range of autoimmune disorders. In 2018, Sitryx raised $30 million Series A funding from an international syndicate of specialist investors including SV Health Investors, Sofinnova Partners, Longwood Fund and GSK. In 2020, Sitryx formed a global licensing and research collaboration with Eli Lilly and Company. Lilly also became an investor in the Company. Sitryx is headquartered in Oxford, UK with offices in the United States.
For more information, please visit www.sitryx.com and engage with us on LinkedIn.